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Background: The current standard of care for management of patients with recurrent pregnancy loss is expectant
management. However, the emotional impact of pregnancy losses and the urgency to conceive often leads
couples to consider a variety of fertility treatments. The objective of this study is to report the time to next
pregnancy and subsequent live birth and miscarriage rates in fertile patients with recurrent pregnancy loss (RPL)
who choose to attempt spontaneous conception compared to those that opt to pursue fertility treatment.
Methods: Retrospective cohort study of one hundred and fifty-eight fertile RPL patients treated at a university-based
fertility center. Patients were followed for a minimum of 6 months. Patients were encouraged to attempt spontaneous
conception, but allowed to initiate fertility treatments (ovarian stimulation, insemination, IVF or PGS) according to their
preferences. Main outcome measures were time to next pregnancy and pregnancy outcome.
Results: For those patients who achieved a spontaneous conception, 88% conceived within 6 months, with a median
time of 2 months and range of 1–10 months. Patients using IUI, IVF and PGS conceived in a median of 3, 4 and
5 months, respectively. The live birth rate and clinical miscarriage rate was not improved with any fertility treatment.
Conclusions: In the fertile RPL patient population, there does not appear to be a benefit to proceeding directly with
fertility treatment. Patients should be encouraged to attempt spontaneous conception for at least 6 months.
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spontaneous pregnancies versus treatment cycles in fertile patients with recurrent pregnancy lossBackground
Recurrent pregnancy loss (RPL) is a condition that af-
fects up to 2-5% of couples attempting conception [1].
After a thorough work-up, including parental karyo-
types, anti-phospholipid antibodies and a uterine cavity
evaluation, almost 50% of patients have no diagnosis for
their recurrent early miscarriages [2,3]. Recommended
treatments for unexplained RPL include nutritional
optimization, emotional support, close surveillance and
ultimately rely on spontaneous conception [4,5]. Live
birth rates with preconception counseling and expectant
management is >60% for most patients, dependent on
maternal age and the number of prior losses [6].* Correspondence: gm807@stanford.edu
Division of Reproductive Endocrinology and Infertility, Department of
Obstetrics and Gynecology, Stanford University Medical Center, 900 Welch
Rd, Suite 15, Palo Alto, CA, USA 94304
© 2015 Perfetto et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The emotional impact of RPL and the urgency to con-
ceive often leads couples to consider a variety of fertility
treatments, such as intrauterine insemination (IUI), con-
trolled ovarian hyperstimulation (COH) and in vitro
fertilization (IVF), to reduce the amount of time to their
next pregnancy, as well as increase their chance of a
pregnancy or live birth sooner. Possible benefits of
undergoing fertility treatments are increased number of
mature oocytes available per cycle, improved luteal
phase support, improved timing of fertilization and an-
euploidy screening in the setting of pre-implantation
genetic screening (PGS) [7]. Benefits have to be balanced
against the potential negative effects of fertility treat-
ments, including but not limited to financial costs, mul-
tiple gestation and ovarian hyperstimulation syndrome.
Although some researchers have reported favorable
live birth outcomes at 5, 10 and 15 years after the initiall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a reasonable amount of time to achieve a live birth [8].
In fact, at the initial visit, most patients desire a more
specific time line on how long it typically takes for a fer-
tile patient with RPL to get pregnant spontaneously,
compared to initiating a fertility treatment immediately.
To determine which option is best for these patients, we
sought to evaluate the time to next pregnancy and sub-
sequent miscarriage rates in fertile patients with RPL
who choose to attempt spontaneous conception com-
pared to those that opt to pursue fertility treatment
immediately.Methods
This is a retrospective cohort study of patients seen in
an RPL clinic at a University-based fertility center from
2010 to 2013. Institutional review board approval was
obtained for this study. Patients with a history of 2 or
more clinical miscarriages (CM) underwent an RPL
work-up recommended by the American Society for Re-
productive Medicine, including blood work for parental
karyotypes, anti-phospholipid antibodies (anti-cardioli-
pin antibody, lupus anticoagulant and beta-2-glycopro-
tein) and a uterine cavity evaluation prior to attempting
conception. After the evaluation was complete, those
RPL patients (<43 years old) without a history of infer-
tility and a history of prior spontaneous pregnancy,
were encouraged to attempt spontaneous conception
for 6 months. In those patients that opted for fertility
treatments sooner, they were offered a range of options,
including: IUI, COH and IVF. In addition, PGS with
24-chromosome screening and day 5 trophectoderm bi-
opsy was offered as an option for those patients inter-
ested in aneuploidy screening during an IVF cycle.
Once the initial evaluation was completed, patients
were followed for a subsequent pregnancy for a mini-
mum of 6 months. Once the patient reported a missed
menses or positive home pregnancy test, the patient
came for a serum quantitative hCG level in our center.
After the initial positive serum test (hCG >5mIU/mL), a
repeat level was drawn 48 hours later and if rising ap-
propriately, the patient was scheduled for a transvaginal
ultrasound at 6–7 weeks of gestation. Pregnancies were
then followed by weekly ultrasound until transfer of care
at 10 weeks gestational age. A clinical miscarriage (CM)
was defined as a loss of pregnancy after a gestational sac
had been identified on ultrasound. A patient with a
serum hCG level >5mIU/mL that never progressed to a
gestational sac on transvaginal ultrasound was diagnosed
with a biochemical pregnancy (BC) or pregnancy of un-
known location (PUL). All pregnancies reported as on-
going had progressed past 20 weeks of gestation. Live
births (LB) were documented by patient report andwhen results were not available, patients were contacted
by their physician for follow-up.
Statistical analysis
The continuous data with a normal distribution was re-
ported as a mean value. A median value with its associ-
ated range was also reported when the data did not have
a normal distribution. The unpaired student t-test was
used to analyze the difference between the means and
the Mann–Whitney test was used for the comparison of
medians. Categorical data was presented as percentages
and a Fisher’s exact test was used to present the differ-
ences between the two groups. A p-value of <0.05 was
considered statistically significant.
Results and discussion
A total of 190 fertile RPL patients completed the initial
evaluation and were followed for a minimum of 6 months
in our center to document subsequent pregnancy outcome
(Additional file 1: Table S1). In the patients in our fertile co-
hort, 4% (n = 7) were diagnosed with anti-phospholipid
antibody syndrome. Of these 7 patients, 1 elected for PGS,
1 elected for IUI and 5 patients became pregnant spontan-
eously. 3% (n = 5) of patients were carriers of a transloca-
tion. Of these 5 patients, 2 elected for PGS and 3 became
pregnant spontaneously. Finally, 2% (n = 3) of patients were
diagnosed with anatomic abnormalities of the uterine
cavity. Of these 3 patients, 1 elected for IVF, 1 elected for
IUI and 1 patient became pregnant spontaneously. Only
the first pregnancy was reported and followed. Of the 190
patients followed, 158 had a laboratory confirmed preg-
nancy (beta hCG >5mIU/mL). The overall pregnancy rate
(PR) at one year was 83% in this cohort.
Of the 158 patients with a positive pregnancy test, 98
occurred spontaneously and 60 occurred with fertility
treatment. Although all of the patients included in this
study were fertile, a large number of them did request to
undergo fertility treatment immediately, rather than try
to conceive spontaneously. Within the treatment group,
there were 23 RPL patients who elected to use IVF-PGS
for aneuploidy screening. Of the patients that used PGS,
8 required more than one cycle to achieve a pregnancy,
ranging between 1 and 4 cycles.
The patients that attempted to conceive spontaneously
were slightly younger than the group that opted for fertil-
ity treatments (34.5 vs. 35.6) but this age difference was
not found to be statistically significant (p = 0.12). The sub-
set of women who used PGS were even older, with an
average age of 36.7 years. The women in both groups had
similar gravidity (3.7 vs. 3.6), number of prior miscarriages
(2.8 vs. 2.6) and body mass index (BMI). Of note, the
women who opted to use fertility treatments had a signifi-
cantly higher rate of prior treatment use, 15% compared
to 3% in the spontaneous conception group. The patients
Table 1 Patient characteristics in those patients who conceived within 12 months of monitoring
Spontaneous All treatments P-value
(n = 98) (n = 60)
Age (mean) 34.5 35.6 0.12
Gravida (mean) 3.7 3.6 0.51
Prior miscarriages (mean) 2.8 2.6 0.18
BMI (mean) 23.8 23.2 0.36
TTP in past pregnancies (median, range) 2.0 (1–12) 3.0 (1–14) 0.03a
Percent of prior pregnancies using infertility treatment 3% 15% 0.03a
aStatistically significant for p < 0.05.
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ger median time to pregnancy in prior pregnancies
(3 months vs. 2 months) (Table 1).
In those pregnancies that were conceived spontaneously,
the median TTP was 2 (1–10) months. The median TTP
in the treatment group (excluding PGS) was significantly
longer at 4 (1–12) months (p < 0.03). When we subcate-
gorized the treatment groups, the median TTP was 3 (1–
9) months for COH with IUI and 4 (1–12) months for
IVF. In the PGS group, the median TTP was 5.0 (2–10)
months, which is significantly longer than those preg-
nancies conceived spontaneously (p < 0.01). Overall,
there was a statistically significant increase in time to
next pregnancy when fertile RPL patients chose to use
fertility treatments (especially IVF-PGS) rather than at-
tempt conception spontaneously.
In those patients who conceived spontaneously, 88% did
so within in 6 months. In the patients that achieved preg-
nancy with fertility treatments (excluding PGS), 84% did
so within 6 months. It took those patients who conceived
with PGS significantly longer to achieve pregnancy, only
70% were pregnant within 6 months (p < 0.05).
The LB/ongoing pregnancy rate was similar between
the three groups, 77% in spontaneous conception group,
73% in the treatment group and 78% in the PGS group.
The CM rate was also similar between the groups, 18%
in the spontaneous conception group, 16% for the treat-
ment group and 13% in the PGS group. There was also no




% of pregnancies conceived within 6 months 88%




BC or PUL 6%
aStatistically significant for p < 0.05.pregnancy group, 11% in the fertility treatment group and
9% in the PGS group (Table 2).
In young fertile RPL patients, there does not appear to
be clinical benefit to proceeding directly to fertility treat-
ments to reduce the time to next pregnancy, increase
the chance of a LB or decrease the chance of a subse-
quent miscarriage. Those RPL patients who conceived
spontaneously in the past and were followed for
6 months had an overall PR of 83% within one year. Of
those RPL patients that got pregnant, 84% did so within
6 months. Using any form of fertility treatment did not
decrease this time to pregnancy, it actually increased the
time significantly. This increase in time may be due to
several factors. Patients in the treatment group were
slightly older and the preparation or set up time for an
IUI or IVF cycle may take 1–2 months. Additionally,
given this is a retrospective review, it is impossible to
say if patients tried to conceive spontaneously before
starting fertility treatment. If patients who were initially
considering treatment conceived spontaneously on their
own, these patients would have increased the number of
early spontaneous conceptions that were reported.
The LB rate is also similar between the spontaneous
conception and fertility treatment groups, confirming
that most fertility treatments do not have a role in the
treatment of RPL. Within the group of RPL patients that
became pregnant spontaneously only 18% had a CM,
which was similar to the RPL patients that used fertility
treatment. The high spontaneous conception rate in justof monitoring
Treatments, p-value PGS only p-value
Excluding PGS (vs. Sp) (vs. Sp)
(n = 37) (n = 23)
84% 0.58 70% 0.05a
4.3 +/− 2.8 0.03a 5.4 +/− 3.0 0.01a
4.0 (1–12) 0.03a 5.0 (2–10) 0.01a
73% 0.65 78% 1.0
16% 1.0 13% 0.76
11% 0.46 0% 0.65
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ment for at least this period of time in this population.
Our findings on PGS are similar to those pregnancies
from spontaneous conception and other fertility treat-
ments. However, due to the small number of patients
that used it, we cannot make any general conclusions
about the utility of PGS in an RPL population. We can
report that those patients that used PGS did not appear
to get pregnant any faster than those that attempted to
conceive spontaneously. This finding supports the
ASRM guideline that PGS does not appear to be benefi-
cial for patients with RPL and is therefore not recom-
mended as a treatment modality in this population. In
addition, the patients that used PGS did not appear to
have better pregnancy outcomes than those women who
conceived spontaneously, with a similar LB and CM
rate. Future studies on the management of RPL patients
will benefit from a prospective study design to enable
randomization of patients to various treatment groups
as well as subgroup analysis of results by age group to
further elucidate the possible effects of differences in
maternal age on study outcomes. In addition, comparing
fertile versus infertile RPL patients is likely to produce dif-
fering clinical outcomes with expectant management ver-
sus infertility treatment, and may better define a role for
IVF in the treatment of patients with RPL.Conclusion
Our study indicates that fertility treatments in a fertile
RPL cohort are unlikely to significantly improve the
chances of achieving an ongoing pregnancy within
6 months of a negative work-up. These findings can be
used to counsel patients with RPL regarding high rates
of fertility and the likelihood of success with expectant
management.Availability of supporting data
A data set supporting the results of this article is included
within the additional files.Additional file
Additional file 1: Table S1. Data set supporting the results of this
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